Eyenovia, Inc. announced that the FDA has approved Eyenovia?s Supplemental New Drug Application (sNDA), adding Coastline International as a contract manufacturer. Coastline will manufacture cartridge subassemblies for Mydcombi, the only FDA-approved tropicamide and phenylephrine hydrochloride fixed combination for mydriasis (office-based pupil dilation).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.07 USD | +7.32% |
|
+22.71% | -48.56% |
Jul. 01 | NovaBay Pharmaceuticals, Eyenovia Begin Co-Promotion Deal Activities | MT |
Jul. 01 | NovaBay Pharmaceuticals, Inc. and Eyenovia, Inc. Commence Co-Promotion Activities | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.56% | 73.85M | |
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |
- Stock Market
- Equities
- EYEN Stock
- News Eyenovia, Inc.
- Eyenovia, Inc. Announces Fda Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production